Literature DB >> 7733315

Acute renal hemodynamic effects of ACE inhibition in diabetic hyperfiltration: role of kinins.

R Komers1, M E Cooper.   

Abstract

Angiotensin converting enzyme (ACE) inhibitors not only reduce angiotensin II (ANG II) levels but also inhibit kinin degradation. The relative roles of ANG II and bradykinin in the acute action of ACE inhibitors on renal hemodynamic parameters in rats after 3 wk of diabetes were explored using antagonists of the ANG II type 1 (AT1) and the bradykinin B2 receptors. Conscious control and streptozotocin diabetic male Sprague-Dawley rats were randomized to receive vehicle, the ACE inhibitor, ramiprilat, the B2-receptor blocker, HOE-140, the AT1-receptor blocker, valsartan, or the combination of ramiprilat and HOE-140. Systolic blood pressure, glomerular filtration rate (GFR), renal plasma flow (RPF), filtration fraction and urinary flow, and sodium excretion were assessed before and during treatment. Diabetic animals had higher GFR and a tendency toward increased RPF and filtration fraction compared with control animals. Acute ramiprilat infusion decreased GFR significantly in diabetic but not in control animals. Valsartan and the combination of ramiprilat and HOE-140 reduced blood pressure to a similar degree to ramiprilat alone, yet did not reduce GFR. No decrease in GFR was observed in any control rat groups. Ramiprilat decreased RPF in diabetic rats but increased RPF in control rats. No such effects on RPF were observed with valsartan. HOE-140 alone did not influence any renal parameter in the diabetic rats. Diabetic rats had increased urinary flow and sodium excretion, but these parameters were not influenced by any drug regimen.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7733315     DOI: 10.1152/ajprenal.1995.268.4.F588

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  11 in total

1.  Renal targeting of captopril selectively enhances the intrarenal over the systemic effects of ACE inhibition in rats.

Authors:  R Folgert G Haverdings; Marijke Haas; Gerjan Navis; Anne-Miek Van Loenen-Weemaes; Dirk K F Meijer; Dick De Zeeuw; Frits Moolenaar
Journal:  Br J Pharmacol       Date:  2002-08       Impact factor: 8.739

Review 2.  Diabetic nephropathy. Its relationship to hypertension and means of pharmacological intervention.

Authors:  T Baba; S Neugebauer; T Watanabe
Journal:  Drugs       Date:  1997-08       Impact factor: 9.546

Review 3.  Optimal strategies for preventing progression of renal disease: should angiotensin converting enzyme inhibitors and angiotensin receptor blockers be used together?

Authors:  R Komers; S Anderson
Journal:  Curr Hypertens Rep       Date:  2000-10       Impact factor: 5.369

Review 4.  Renal protection and antihypertensive drugs: current status.

Authors:  A Salvetti; P Mattei; I Sudano
Journal:  Drugs       Date:  1999-05       Impact factor: 9.546

Review 5.  Diabetic vascular injury and ACE. Potential for pharmacological prevention of complications of later life.

Authors:  M E Cooper; D Vranes; J R Rumble
Journal:  Drugs Aging       Date:  1996-01       Impact factor: 3.923

6.  Role of angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers in the prevention of progression of renal disease.

Authors:  C V Ram; P Vergne-Marini
Journal:  Curr Hypertens Rep       Date:  1999-10       Impact factor: 5.369

7.  Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study.

Authors:  C E Mogensen; S Neldam; I Tikkanen; S Oren; R Viskoper; R W Watts; M E Cooper
Journal:  BMJ       Date:  2000-12-09

Review 8.  Pathophysiology of the diabetic kidney.

Authors:  Volker Vallon; Radko Komers
Journal:  Compr Physiol       Date:  2011-07       Impact factor: 9.090

Review 9.  Targeting the renin-angiotensin system in patients with renal disease.

Authors:  Mark A J Devonald; Fiona E Karet
Journal:  J R Soc Med       Date:  2002-08       Impact factor: 18.000

Review 10.  A Novel Category of Anti-Hypertensive Drugs for Treating Salt-Sensitive Hypertension on the Basis of a New Development Concept.

Authors:  Makoto Katori; Masataka Majima
Journal:  Pharmaceuticals (Basel)       Date:  2010-01-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.